301 related articles for article (PubMed ID: 28462446)
1. Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer.
Riedl CC; Pinker K; Ulaner GA; Ong LT; Baltzer P; Jochelson MS; McArthur HL; Gönen M; Dickler M; Weber WA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1428-1437. PubMed ID: 28462446
[TBL] [Abstract][Full Text] [Related]
2. 2-[
Vogsen M; Naghavi-Behzad M; Harbo FG; Jakobsen NM; Gerke O; Asmussen JT; Nissen HJ; Dahlsgaard-Wallenius SE; Braad PE; Jensen JD; Ewertz M; Hildebrandt MG
Sci Rep; 2023 Apr; 13(1):5552. PubMed ID: 37019987
[TBL] [Abstract][Full Text] [Related]
3. Response Monitoring in Metastatic Breast Cancer: A Prospective Study Comparing
Vogsen M; Harbo F; Jakobsen NM; Nissen HJ; Dahlsgaard-Wallenius SE; Gerke O; Jensen JD; Asmussen JT; Jylling AMB; Braad PE; Vach W; Ewertz M; Hildebrandt MG
J Nucl Med; 2023 Mar; 64(3):355-361. PubMed ID: 36207136
[TBL] [Abstract][Full Text] [Related]
4. TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.
Ho KC; Fang YD; Chung HW; Liu YC; Chang JW; Hou MM; Yang CT; Cheng NM; Su TP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2155-2165. PubMed ID: 27260520
[TBL] [Abstract][Full Text] [Related]
5. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
[TBL] [Abstract][Full Text] [Related]
6. Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0.
Odawara S; Kitajima K; Katsuura T; Kurahashi Y; Shinohara H; Yamakado K
Eur J Radiol; 2018 Apr; 101():65-71. PubMed ID: 29571803
[TBL] [Abstract][Full Text] [Related]
7. FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST.
Depardon E; Kanoun S; Humbert O; Bertaut A; Riedinger JM; Tal I; Vrigneaud JM; Lasserre M; Toubeau M; Berriolo-Riedinger A; Dygai-Cochet I; Fumoleau P; Brunotte F; Cochet A
PLoS One; 2018; 13(7):e0199529. PubMed ID: 30011328
[TBL] [Abstract][Full Text] [Related]
8. The Impact That Number of Analyzed Metastatic Breast Cancer Lesions Has on Response Assessment by 18F-FDG PET/CT Using PERCIST.
Pinker K; Riedl CC; Ong L; Jochelson M; Ulaner GA; McArthur H; Dickler M; Gönen M; Weber WA
J Nucl Med; 2016 Jul; 57(7):1102-4. PubMed ID: 26985059
[TBL] [Abstract][Full Text] [Related]
9. Prospective comparison of early interim
Su TP; Huang JS; Chang PH; Lui KW; Hsieh JC; Ng SH; Chan SC
BMC Cancer; 2021 Aug; 21(1):908. PubMed ID: 34376155
[TBL] [Abstract][Full Text] [Related]
10. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
[TBL] [Abstract][Full Text] [Related]
11. Predictive and prognostic value of FDG-PET/CT imaging and different response evaluation criteria after primary systemic therapy of breast cancer.
Tőkés T; Kajáry K; Szentmártoni G; Lengyel Z; Györke T; Torgyík L; Somlai K; Tőkés AM; Kulka J; Dank M
Breast Cancer; 2017 Jan; 24(1):137-146. PubMed ID: 26979062
[TBL] [Abstract][Full Text] [Related]
12. 3'-Deoxy-3'-
Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
[TBL] [Abstract][Full Text] [Related]
13. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
14. FDG-PET/CT Versus Contrast-Enhanced CT for Response Evaluation in Metastatic Breast Cancer: A Systematic Review.
Helland F; Hallin Henriksen M; Gerke O; Vogsen M; Høilund-Carlsen PF; Hildebrandt MG
Diagnostics (Basel); 2019 Aug; 9(3):. PubMed ID: 31461923
[TBL] [Abstract][Full Text] [Related]
15. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using
Kitajima K; Watabe T; Nakajo M; Ishibashi M; Daisaki H; Soeda F; Tanemura A; Kanekura T; Yamazaki N; Ito K
Jpn J Radiol; 2022 Jan; 40(1):75-85. PubMed ID: 34287739
[TBL] [Abstract][Full Text] [Related]
16. The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.
Zerizer I; Al-Nahhas A; Towey D; Tait P; Ariff B; Wasan H; Hatice G; Habib N; Barwick T
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1391-9. PubMed ID: 22644713
[TBL] [Abstract][Full Text] [Related]
17. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
Skougaard K; Nielsen D; Jensen BV; Hendel HW
J Nucl Med; 2013 Jul; 54(7):1026-31. PubMed ID: 23572497
[TBL] [Abstract][Full Text] [Related]
18. Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung Cancer.
Beer L; Hochmair M; Haug AR; Schwabel B; Kifjak D; Wadsak W; Fuereder T; Fabikan H; Fazekas A; Schwab S; Mayerhoefer ME; Herold C; Prosch H
Clin Nucl Med; 2019 Jul; 44(7):535-543. PubMed ID: 31021918
[TBL] [Abstract][Full Text] [Related]
19. Response to neoadjuvant chemotherapy for breast cancer judged by PERCIST - multicenter study in Japan.
Kitajima K; Nakatani K; Yamaguchi K; Nakajo M; Tani A; Ishibashi M; Hosoya K; Morita T; Kinoshita T; Kaida H; Miyoshi Y
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1661-1671. PubMed ID: 29754160
[TBL] [Abstract][Full Text] [Related]
20. Response criteria in solid tumors (PERCIST/RECIST) and SUV
Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
